Displaying 13221 - 13230 of 13794
Drupal spam blocked by CleanTalk.
Author yearsort descending
Construction of Engineered Bifunctional Enzymes and Their Overproduction in Aspergillus niger for Improved Enzymatic Tools To Degrade Agricultural By-Products. Levasseur A, Navarro D, Punt PJ, Belaich JP, Asther M, Record E. 2005
Conventional and diffusion-weighted MR imaging of cerebral aspergillosis. Keyik B, Edguer T, Hekimoglu B. 2005
Aspergillosis in mammals and birds: impact on veterinary medicine Tell LA. 2005
Posaconazole: a broad-spectrum triazole antifungal. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. 2005
A novel glyco-conjugate vaccine against fungal pathogens. Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, Norelli F, Bellucci C, Polonelli L, Costantino P, Rappuoli R, Cassone A. 2005
Mycotoxigenicity of clinical and environmental Aspergillus fumigatus and A. flavus isolates. Kosalec I, Pepeljnjak S. 2005
Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. Glasmacher A, Cornely OA, Orlopp K, Reuter S, Blaschke S, Eichel M, Silling G, Simons B, Egerer G, Siemann M, Florek M, Schnitzler R, Ebeling P, Ritter J, Reinel H, Schutt P, Fischer H, Hahn C, Just-Nuebling G. 2005
Systemic fungal infections caused by Aspergillus species: epidemiology, infection process and virulence determinants. Brakhage AA. 2005
Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients. Waterhouse TH, Redmann S, Duffull SB, Eccleston JA. 2005
Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy. Lionakis MS, Lewis RE, Chamilos G, Kontoyiannis DP. 2005


Subscribe to Search